Valeant Pharma's (VRX) Relistor Said to Draw Interest from Potential Buyers

August 5, 2016 12:15 PM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

(Updated - August 5, 2016 12:17 PM EDT)

Valeant Pharma's (NYSE: VRX) Relistor said to have drawn interest from potential buyers, according to Bloomberg.

UPDATE - Other drugmakers may be interested in the asset, sources said.

Relistor could get around $400 - $500 million in a potential sale.

News comes as Valeant works to get a $30 billion debtload under control, while also looking to ease public concerns over drug pricing and the company's business practices, which have taken center stage this year.

Progenics Pharma (Nasdaq: PGNX) is Valeant's partner on Relistor. The drug is indicated to treat constipation brought on by taking opioids for chronic, non-cancer pain.

Shares of Valeant are down 0.7 percent.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Mergers and Acquisitions, Rumors, Short Sales, Trader Talk

Add Your Comment